Clinical trials
Hematologic Neoplasms trials in Austria
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
15 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2007 | 1 |
| 2009 | 2 |
| 2011 | 2 |
| 2012 | 3 |
| 2015 | 1 |
| 2017 | 1 |
| 2018 | 1 |
| 2020 | 1 |
| 2021 | 3 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 6 |
| Recruiting | 3 |
| Terminated | 3 |
| Active, not recruiting | 1 |
| Enrolling by invitation | 1 |
| Unknown status | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Bristol-Myers Squibb | 2 |
| Novartis Pharmaceuticals | 2 |
| Amgen | 1 |
| Arbeitsgemeinschaft medikamentoese Tumortherapie | 1 |
| Centre Hospitalier Universitaire Vaudois | 1 |
| Cogent Biosciences, Inc. | 1 |
| Eli Lilly and Company | 1 |
| Elisabethinen Hospital | 1 |
| Kite, A Gilead Company | 1 |
| Medical University of Vienna | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Hematologic Neoplasms | 15 |
| Hematologic Diseases | 3 |
| Bone Marrow Diseases | 2 |
| Invasive Fungal Infections | 2 |
| Leukemia | 2 |
| Leukemia, Myeloid | 2 |
| Lymphoma, Large B-Cell, Diffuse | 2 |
| Neoplasms | 2 |
| Autoimmune Diseases | 1 |
| Blood Protein Disorders | 1 |
Trials
Showing 26 to 15 of 15. Each trial links to its page on Pharma Observatory.
No trials match these filters.
Try a different keyword, or clear a filter.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.